title: Bioisosterism in drug design: identification of and structure-activity relationships in a series of glycine anilide ACAT inhibitors.
abstract: To examine the effects of bioisosteric replacement on the biological activity of our previously disclosed disubstituted urea inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase (ACAT), we prepared a series of N'-substituted and N',N'-disubstituted glycine anilides. These compounds were tested for the ability to inhibit ACAT in vitro and lower plasma total cholesterol in cholesterol-fed rats given a single high-fat, high-cholesterol meal. ACAT inhibitory potency was greatest in compounds containing 2,6-diisopropyl substituents in the anilide portion with the glycine nitrogen substituted by a 1,1-diphenylmethyl moiety. Small improvements in potency in vitro were obtained by substitution of electron donating groups in the 2-, 3- or 5-positions of the aryl rings of the 1,1-diphenylmethyl moiety, but not by substitution in the 4-position. In vitro potency was maintained, but not improved by acylation of the glycine nitrogen. Through a QSAR analysis of in vitro ACAT inhibition for this set of compounds, an equation could be derived which accounted for 85% of the variance in the dataset. An optimal clogp of 6.65 was found, comparable to that found for other series of ACAT inhibitors. In general, compounds from this series displayed inhibitory potency against ACAT in vitro and hypocholesterolemic activity in the in vivo rat model of hypercholesterolemia comparable to that found with the ureas.
authors.affiliation: Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
authors.forename: W H
authors.initials: WH
authors.lastname: Roark
authors.forename: J
authors.initials: J
authors.lastname: Padia
authors.forename: G L
authors.initials: GL
authors.lastname: Bolton
authors.forename: C J
authors.initials: CJ
authors.lastname: Blankley
authors.forename: A D
authors.initials: AD
authors.lastname: Essenburg
authors.forename: R L
authors.initials: RL
authors.lastname: Stanfield
authors.forename: R F
authors.initials: RF
authors.lastname: Bousley
authors.forename: B R
authors.initials: BR
authors.lastname: Krause
authors.forename: B D
authors.initials: BD
authors.lastname: Roth
mesh_terms: D000214:Acyl Coenzyme A / Q000187:drug effects; D000813:Anilides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D000818:Animals; D000924:Anticholesteremic Agents / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D005998:Glycine / Q000737:chemistry* / Q000494:pharmacology; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D008861:Microsomes / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D000214:Acyl Coenzyme A; D000813:Anilides; D000924:Anticholesteremic Agents; C017585:oleoyl-coenzyme A; D002785:Sterol O-Acyltransferase; D005998:Glycine